People taking certain drugs for schizophrenia, manic-depression, autism, dementia or several other psychiatric disorders should be carefully watched for signs they are developing diabetes, obesity or high cholesterol, four medical societies say.
The recommendation follows recent studies that link those potential side effects to certain anti-psychotic drugs.
The statement deals with six now available in the United States: Abilify, Clozaril, Geodon, Risperdal, Seroquel and Zyprexa.
The recommendation, released last week, comes from the American Diabetes Association, the American Psychiatric Association, the North American Association for the Study of Obesity and the American Association of Clinical Endocrinologists. It appears in the February issue of the journal Diabetes Care.
The medications differ in their risks of promoting the various side effects, the statement says. So a patient who develops a problem with one drug could be gradually switched over to another drug with less potential for that problem. For example, a switchover should be considered if a patient has a weight gain of 5 percent or more, the statement says.
Obesity and diabetes, like high cholesterol, raise a person’s risk of heart disease.
The recommendation says doctors should screen patients before starting them on such a drug or as soon as possible afterward, noting such things as a history of obesity and diabetes in the patient and the family, and the patient’s weight, blood pressure and cholesterol levels. Doctors should also monitor the patient once therapy has begun.
Patients and family members should be informed of the potential for the side effects, and be told of signs of diabetes and especially those of a life-threatening complication called diabetic ketoacidosis, the statement says. That complication is marked by such symptoms as weight loss, nausea, vomiting, rapid breathing and dehydration.
That complication has appeared in some people using anti-psychotics, and it was an early tip-off that the drugs might be linked to diabetes.